Maiwei Biomedical-B (02493): 9MW2821 reported the latest clinical data at the 2026 European Society for Medical Oncology Gynecologic Oncology Annual Meeting in the form of oral presentation and poster presentation.

Wise Finance News APP, Maxwis Bio-B (02493) announced that the company will present the latest results of the Phase I/II clinical study of the innovative targeted Nectin-4 ADC drug 9MW2821 (Bulumtatug Fuvedotin, BFv) for the treatment of recurrent or metastatic cervical cancer patients in oral presentation form at the 2026 European Society for Medical Oncology Gynecological Cancers Congress (ESMO Gynaecological Cancers Congress) to be held in Copenhagen, Denmark from June 17 to June 19, 2026.